Search

everythinglearnresearchcommunity

for

Search:↓

Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.

Patients with alopecia areata prefer effective, safe, and convenient treatments, especially topical ones.

Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

Lighter skin types respond better to narrowband UVB therapy for cutaneous T-cell lymphoma than darker skin types.

Refugee patients face long wait times for dermatology care, worsening health disparities.

New small molecule drugs show promise in treating complex skin diseases but need more safety research.

Precision medicine is crucial for early diagnosis and personalized treatment in prediabetes.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Recognizing and treating related skin conditions can improve atopic dermatitis management.

AA patients with comorbid conditions face more severe hair loss and need specific treatments.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Hair follicles can be used to study gene expression and understand conditions like COPD.

Hair oils can worsen seborrheic dermatitis in black patients.

Pharmacists play a crucial role in patient care and optimizing treatment outcomes.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.

Scalp cooling therapy helps preserve hair during chemotherapy for most patients.

Low dose methotrexate does not increase hair fall and may reduce it.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

Human hair contains more glycosaminoglycans in children than adults, and these compounds decrease with age, possibly affecting hair thickness.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

A TNFAIP3 gene mutation can cause unusual and varied symptoms of lupus and Sjogren's syndrome.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.